Migraine: Diagnosis and treatment

Australian Family Physician

Volumn 34, Issue 8, 2005, Pages 627-632

  Joubert, Jacques ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; VALPROIC ACID;

BEHAVIOR THERAPY; DIET THERAPY; GENERAL PRACTICE; HUMAN; METHODOLOGY; MIGRAINE; PAIN ASSESSMENT; PATIENT EDUCATION; REVIEW;

ANALGESICS; BEHAVIOR THERAPY; DIET THERAPY; DOPAMINE ANTAGONISTS; DROPERIDOL; FAMILY PRACTICE; HUMANS; MIGRAINE DISORDERS; PAIN MEASUREMENT; PATIENT EDUCATION; VALPROIC ACID;

EID: 26944434830     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Gallagher RM. What do patients want from acute migraine treatment?. Cephalalgia 2004;24(Suppl)20:8-15.
2. Goadsby PJ. Migraine: diagnosis and management. Intern Med J 2003;33:436-42.
3. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol 2000;57:418-20.
4. Bahra A, Matharu MS, Buchel C, Frackowiak RSJ, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet 2001;357:1016-7.
5. Bowyer SM, Mason KM, Moran JE, Tepley N, Mitsias PD. Cortical hyperexcitability in migraine patients before and after sodium valproate treatment. J Clin Neurophysiol 2005;22:65-7.
6. Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat Med 2004;10:685-92.
7. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003;25:2506-38.
8. Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia 2004;(Suppl 2):2-7.
9. Ashkenazi A, Silberstein S. The evolving management of migraine. Curr Opin Neurol 2003;16:341-5.
10. Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache 1998;38:497-506.
11. Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal grey matter dysfunction in migraine: cause or the burden of illness in migraine. Headache 2001;41:629-37.
12. Wong TY, Klein R, Sharrett AR, et al. Cerebral white matter lesions, retinopathy and incident clinical stroke. JAMA 2002;288:67-74.
13. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Shoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared to oral sumatriptan for migraine. Lancet 1995;346:923-6.
14. Elrington G. Migraine: diagnosis and management. J Neurol Neurosurg Psychiatry 2002;72(Suppl 2):10-15.
15. Myllyla VV, Havanka H, Herral L, et al. Tolfanemic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double blind, randomised, controlled, parallel group study. Headache 1998;38:201-7.
16. Silberstein SD, Young WB, Mendizabal JE, et al. Acute migraine treatment with droperidol: a randomised, double blind, placebo controlled trial. Neurology 2003;60:315-21.
17. Silberstein SD, Olesen J, Bousser M-G, et al on behalf of the International Headache Society. The International Classification of Headache Disorders. 2nd ed (ICHD-II): revision of criteria for 8.2 Medication overuse headache. Cephalalgia 2005;25:460-5.
18. Millichap JG, Yee MM. The diet factor in pediatric and adolescent migraine. Pediatr Neurol 2003;28:9-15.
19. Gaus W, Hogel J. Studies on the efficacy of unconventional therapies. Problems and designs. Azneimittelforshung 1995;45:88-92.
20. Bic Z, Blix GG, Hopp HP, Leslie FM, Schell MJ. The influence of a low fat diet on incidence and severity of migraine headaches. J Womens Health Gend Based Med 1999;5:623-30.
21. Jansen SC, van Dusselforp M, Bottema KC, Dubois AEJ. Intolerance to dietary biogenic amines: a review. Ann Allergy Asthma Immunol 2003;91:3.
22. D'Andrea G, Perini F, Terrazzino S, Nordera GP. Contributions of biochemistry to the pathogenesis of primary headaches. Neurol Sci 2004;25(Suppl 3):S89-92.
23. Penzien DB, Rains JC, Andrasik F. Behavioural management of recurrent headache: three decades of experience and empiricism. Appl Psychophysiol Biofeedback 2002;27:163-81.
24. Evers S, Vollmer-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin A in the prophylactic treatment of migraine: a randomised, double blind, placebo controlled study. Cephalalgia 2004;24:838-43.